Levocarnitine To Protect the Liver From Chemotherapy for Leukemia or Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This phase III trial compares the effect of adding levocarnitine to chemotherapy versus
chemotherapy alone in protecting the liver in patients with leukemia and lymphoma. Standard
of care chemotherapy treatment for leukemia and lymphoma includes a type of chemotherapy
named asparaginase, given either as the drug pegaspargase, or a similar drug, calaspargase
pegol. This type of chemotherapy can cause severe liver damage. Levocarnitine is a drug used
to provide extra carnitine, a naturally occurring nutrient that is part of a typical diet and
is also made by the body. Carnitine is important to keep the liver healthy and may be able to
prevent damage to the liver from chemotherapy and other drugs. Taking levocarnitine may
reduce the rate of severe liver damage caused by asparaginase chemotherapy in patients with
leukemia and lymphoma.